<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04631874</url>
  </required_header>
  <id_info>
    <org_study_id>CTC-IND-CDFF0318_1</org_study_id>
    <nct_id>NCT04631874</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Compare Pharmacokinetics of the &quot;CDFF0318&quot; and &quot;Champix Tab. 1mg&quot;</brief_title>
  <official_title>A Phase 1 Clinical Trial to Compare and Evaluate Safety and Pharmacokinetic Characteristics After Administration of the &quot;CDFF0318&quot; and &quot;Champix Tab. 1mg (Varenicline Tartrate)&quot; in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CTC Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CTC Bio, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1 Clinical Trial to Compare and Evaluate Safety and Pharmacokinetic Characteristics&#xD;
      after Administration of the &quot;CDFF0318&quot; and &quot;Champix Tab. 1mg (Varenicline tartrate)&quot; in&#xD;
      Healthy Male Volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 24, 2019</start_date>
  <completion_date type="Actual">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (AUC0-t)</measure>
    <time_frame>72 hours</time_frame>
    <description>AUC0-t of &quot;CDFF0318&quot; and &quot;Champix Tab. 1mg&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (Cmax)</measure>
    <time_frame>72 hours</time_frame>
    <description>Cmax of &quot;CDFF0318&quot; and &quot;Champix Tab. 1mg&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (Vital sign)</measure>
    <time_frame>72 hours</time_frame>
    <description>Blood pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (Vital sign)</measure>
    <time_frame>72 hours</time_frame>
    <description>Heart rate (beats/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (12-lead ECG)</measure>
    <time_frame>72 hours</time_frame>
    <description>ventricular rate (beats/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (12-lead ECG)</measure>
    <time_frame>72 hours</time_frame>
    <description>PR interval (msec)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (Laboratory tests)</measure>
    <time_frame>72 hours</time_frame>
    <description>Creatinine [mg/dL]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (Laboratory tests)</measure>
    <time_frame>72 hours</time_frame>
    <description>AST, ALT [IU/L]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (Laboratory tests)</measure>
    <time_frame>72 hours</time_frame>
    <description>eGFR [mL/min/1.73m^2]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (Adverse events)</measure>
    <time_frame>72 hours</time_frame>
    <description>Adverse events were collected regardless of the time point when the subject complained of symptoms.&#xD;
Adverse events were assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Smoking Cessation</condition>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Sequence A(RT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reference drug (Champix) -&gt; washout -&gt; test drug (CDFF0318)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B(TR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test drug (CDFF0318) -&gt; washout -&gt; reference drug (Champix)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDFF0318, Champix</intervention_name>
    <description>CDFF0318: Varenicline salt changed Champix: Varenicline tartrate</description>
    <arm_group_label>Sequence A(RT)</arm_group_label>
    <arm_group_label>Sequence B(TR)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects aged 19 to 45 years&#xD;
&#xD;
          -  a body mass index of 18.0-30.0 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with disease history or current disease of clinically significant liver,&#xD;
             kidney, nervous system, respiratory system, endocrine system, blood/tumor, urinary&#xD;
             system, cardiovascular system, etc.&#xD;
&#xD;
          -  Subjects with a history of gastrointestinal diseases or gastrointestinal surgery that&#xD;
             may affect the absorption of investigational drugs&#xD;
&#xD;
          -  Subjects with a history of hypersensitivity reactions or clinically significant&#xD;
             hypersensitivity reactions to drugs containing varenicline and other drugs&#xD;
             (ketoprofen, aspirin, antibiotics, etc.)&#xD;
&#xD;
          -  Subjects who have an abnormal diet that may affect the absorption, distribution,&#xD;
             metabolism, and excretion of the drug, or who eat food that may affect drug metabolism&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min-Kyu Park</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungbuk National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 27, 2020</study_first_submitted>
  <study_first_submitted_qc>November 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>November 15, 2020</last_update_submitted>
  <last_update_submitted_qc>November 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

